Delaying the onset of type 1 diabetes

KSR acted as the External Assessment Group (EAG) for NICE on a recent technology appraisal of teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes.

“This is a genuinely exciting recommendation. For the first time, we have a treatment that can give people diagnosed at an early stage of type 1 diabetes precious extra time before they need to manage the full demands of the condition” stated Helen Knight, director of medicines evaluation at NICE.

Helen added, “The evidence shows teplizumab can delay the onset of symptomatic diabetes by an average of nearly three years. As always, our decision is rigorous, transparent and based on the best available evidence, striking a balance between clinical benefit and value for the taxpayer. We’re pleased to be able to recommend it for NHS use, and we will continue to scan the horizon for further innovations so we can continue to get the best care to patients as quickly as possible.”

Further information on the NICE website